Saluda Medical, a medical equipment manufacturing company based in Artarmon, NSW, has raised $150,000,000 in an unknown funding round from investors including TPG, Wellington Management, T. Rowe Price, Action Potential Venture Capital, and Redmile Group. Saluda Medical is revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders. The company's first product, the Evoke® System, is the only ECAP-controlled closed-loop spinal cord stimulation (SCS) system and is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain.

The Evoke System is proven to be superior to open-loop SCS for the treatment of overall trunk and/or limb pain. The company's 12-month and 24-month studies are poised to set new clinical standards for long-term pain relief and improvements in physical and emotional functioning, sleep quality, and health-related quality of life.

Saluda Medical is a privately held company with headquarters in Artarmon, New South Wales, Australia, and has offices in Bloomington, MN, USA; Harrogate, UK; and Terheijden, Netherlands. The Evoke System is FDA-approved and will be available when the company implements its full commercial release in 2023. To learn more about Saluda Medical, visit their latest funding round at https://founderlodge.com/round/Saluda-Medical-raises-150000000-Unknown-2023-04-17-Jim-Schuermann-MTIyMTU